Benitec Biopharm Stock Price, News & Analysis

Benitec Biopharma (Nasdaq: BNTC) has announced the pricing of a combined stock offering expected to raise $30 million in gross proceeds. The offering consists of:

- An underwritten offering of 1,443,000 common stock shares (or pre-funded warrants)

- A concurrent registered direct offering of 900,000 shares with Suvretta Capital

Each share is priced at $13.00, while pre-funded warrants are priced at $12.9999 with a $0.0001 exercise price. The offerings are expected to close on March 26, 2025. The company plans to use the proceeds for product candidate development, working capital, and general corporate purposes. Leerink Partners and TD Cowen are serving as bookrunning managers, with Citizens Capital Markets as lead manager.

Benitec Biopharma (NASDAQ: BNTC) has reported positive interim clinical results from its Phase 1b/2a study of BB-301 gene therapy for Oculopharyngeal Muscular Dystrophy (OPMD). Three subjects treated with BB-301 showed significant improvements in swallowing function:

- Subject 1 achieved durable improvements 12 months post-treatment with 37% reduction for thin liquid, 18% for solid food, and 29% for thick liquids in swallowing efficiency
- Subject 2 reached a clinically normal swallowing profile at 12 months with 91% symptom reduction
- Subject 3 achieved a clinically normal swallowing profile at 3 months with 68% symptom reduction

The study has treated five subjects safely with the low-dose BB-301, with the sixth and final subject of Cohort 1 expected to receive treatment in Q2 2025. No severe adverse events have been reported. Results will be presented at the 2025 Muscular Dystrophy Association Conference in Dallas.

Benitec Biopharma (NASDAQ: BNTC), a clinical-stage biotechnology company specializing in gene therapy and 'Silence and Replace' DNA-directed RNA interference (ddRNAi) platform, has announced its participation in three major healthcare conferences in March 2025.

The company will present at:

• TD Cowen 45th Annual Health Care Conference on March 5, 2025 (9:50-10:20 AM EST)
• Leerink Partners Global Healthcare Conference on March 12, 2025 (9:20-9:50 AM EST)
• 2025 Muscular Dystrophy Association Clinical & Scientific Conference in Dallas, TX, featuring two sessions on March 18-19, 2025, focusing on Oculopharyngeal Muscular Dystrophy and Clinical Trial Updates

All presentations will be available via live webcast, and one-on-one meetings can be scheduled with management.

Benitec Biopharma (NASDAQ: BNTC) has released its Q2 2025 financial results and provided updates on its BB-301 Phase 1b/2a clinical trial for Oculopharyngeal Muscular Dystrophy (OPMD). The fifth subject was safely treated in February 2025, with interim results showing durable, clinically meaningful improvements in swallowing function for the first subjects treated.

Financial highlights for Q2 2025 include:

• Revenue: $0.0 million
• Total expenses: $8.6 million (up from $6.9 million in Q2 2024)
• Net loss: $7.4 million, or ($0.33) per share
• Cash position: $78.3 million as of December 31, 2024

The company plans to begin treating a second cohort with a higher dose of BB-301 later in the year. An interim clinical study update will be presented at the 2025 Muscular Dystrophy Association Conference on March 19, 2025.

Benitec Biopharma (NASDAQ: BNTC) announced the acceptance of a late-breaking oral abstract for their BB-301 Phase 1b/2a Clinical Treatment Study at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference. The presentation, scheduled for March 19, 2025, will provide interim updates on the first three subjects treated with BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD) with moderate dysphagia.

The company previously reported in October 2024 that the first two subjects showed durable, clinically meaningful improvements in swallowing function following BB-301 treatment. The therapy, based on Benitec's proprietary 'Silence and Replace' DNA-directed RNA interference platform, aims to address dysphagia, a severe, life-threatening complication of OPMD. Additional clinical updates for enrolled subjects are planned for Q4 2025.

Benitec Biopharma (NASDAQ: BNTC), a clinical-stage biotechnology company specializing in gene therapy and novel genetic medicines based on their proprietary 'Silence and Replace' DNA-directed RNA interference (ddRNAi) platform, has announced their participation in three upcoming conferences.

The company will attend the Muscular Dystrophy Association Gene Therapy Summit in Tucson, AZ from January 28-30, 2025, followed by the Guggenheim SMID Cap Biotech Conference in New York, NY on February 5, 2025, which will feature one-on-one meetings. Additionally, Benitec will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, at 2:00 PM EST, offering both a presentation and one-on-one meeting opportunities. The Oppenheimer presentation will be available via live webcast.

Benitec Biopharma (NASDAQ: BNTC), a clinical-stage biotechnology company focused on gene therapy and developing genetic medicines using their proprietary 'Silence and Replace' DNA-directed RNA interference platform, has announced their participation in two upcoming investor conferences in December 2024.

The company will participate in the Piper Sandler Annual Healthcare Conference on December 4, 2024, at 12:00 PM EST in New York, featuring a fireside discussion and one-on-one meetings. Additionally, they will attend the Oppenheimer Movers in Rare Disease Summit on December 12, 2024, from 9:50-10:40 AM EST in New York, participating in a panel discussion and one-on-one meetings.

Benitec Biopharma (NASDAQ: BNTC) has released its Q1 2025 financial results and operational updates. The company reported positive interim clinical study data for BB-301 in treating Oculopharyngeal Muscular Dystrophy (OPMD). The first subject showed 35-40% improvement in dysphagic symptoms at 270 days, while the second subject achieved a clinically normal swallowing profile at 180 days. A third subject was treated in October 2024, with a fourth expected in December.

Financial results show no revenue for Q1 2025, with total expenses of $5.8 million. The company reported a net loss of $5.1 million ($0.48 per share) and held $67.8 million in cash as of September 30, 2024.

Benitec Biopharma (NASDAQ: BNTC), a clinical-stage biotechnology company focused on gene therapy and developing genetic medicines using their proprietary 'Silence and Replace' DNA-directed RNA interference (ddRNAi) platform, has announced their participation in the Guggenheim Securities Healthcare Conference. CEO Jerel A. Banks, M.D., Ph.D., will present at the conference on November 11, 2024, at 2:30 PM in Boston. The presentation will be conducted in a fireside chat format with opportunities for one-on-one meetings, and will be available via live webcast.